Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination
with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in
relapsed/refractory EBV+ lymphomas.